The current concept aims towards to modify the immuno response by inducing a immuno tolerance with two factors: 1. Modifying the stent surface with a surface characteristic in a range of 1 - 5 µ, that is considered to be not foreign for the body and 2. to add small traces to immuno suppressant drug. With this concept the wound healing is facilitated without suppressing the normal wound-healing but the prolonged re-stenotic proliferation is avoided. Only small traces of an immuno suppressant drug locally are required, preferably the drug is applied without a carrier to the surfaces. The use of a biodegradable or non-biodegradable is feasible as well.
